Mean liver weight (g) (A), liver weight/body ratio (B), hepatic triglyceride (mg/g) (C) and hepatic steatosis quantification (% area) (D) upon completion of the treatment phase. by Elsie D. Oduor (22521785)

Effect of pyruvic acid on ATP production and A1254-induced decrease of membrane mitochondrial potential (mΔΨ) in SH-SY5Y cells. by Stefania Cocco (759155)

IL-1Ra expressed by MSCs decreased Th17 differentiation. by Kijun Lee (4888660)

Infection with BVDV R₂, R₃ and R₅ leads to a decrease in dead cells. by Eliana F. Castro (581093)

Decrease of muscle weakness and degeneration with mutants of UPS components. by Cécile Ribot (11944875)

Pretreatment of Huh-7.5.1 cells with PF-429242 results in a robust decrease in intracellular viral RNA for all four DENV serotypes. by Anastasia Hyrina (3860455)

Additional behavioral patterns in the 5€, 100€, and 1000€ treatments. by Pablo Brañas-Garza (336425)

Decreased cellular infiltration into lungs of <i>Ifi35</i> deficient mice after H5N1-VN/PR8 infection. by Anshu P. Gounder (626041)

Decreased expression of adipogenesis-related genes by baicalein in early stage of adipogenesis. by Yukari Nakao (3138795)

“…Cells were prepared as described in the legend of Fig 5B. The data are presented as the value relative to that of the undifferentiated cells and are shown as the means ± S.D. from three experiments. …”

Fig 5 - by Maria Alice Miranda Bezerra Medeiros (11752002)

LY5 does not inhibit growth of <i>ex vivo</i> pulmonary metastasis. by Peter Y. Yu (4281448)

Revisiting the sealed heating method–V158411 decreases Chk1 nuclear immunofluorescence in HT29 cells heated in a low well volume. by Andrew J. Massey (239469)

Three-dimensional (3D) Collagen Type I gel formula (5 mg/mL). by Melissa A. MacIver (12850566)

Subjects:

Medication tolerability, discontinuations, adherence over the 8-week study period. by Judith I. Tsui (5983160)

Subjects:

Medication satisfaction over 8-week study medication period. by Judith I. Tsui (5983160)

Subjects:

Main results: Changes in primary and secondary outcomes from baseline to 8 weeks in the PETER PAIN trial. by Judith I. Tsui (5983160)

Subjects:

Baseline characteristics of PETER PAIN study participants: People with HIV, chronic pain, and heavy alcohol use (n = 45). by Judith I. Tsui (5983160)

Subjects:

Whole brain volume change over 5 years using the SIENA pipeline. by Renxin Chu (5169857)

Participants characteristics. by Sakiko Fukui (387048)

Subjects:

A mutation in <i>dSK</i> results in decreased long-term memory 24 h after 5 h ‘extended’ training session. by Ahmad N. Abou Tayoun (326696)